Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Change in Cash (2016 - 2025)

Historic Change in Cash for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $13.0 million.

  • Celldex Therapeutics' Change in Cash rose 30493.69% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$362000.0, marking a year-over-year decrease of 10237.14%. This contributed to the annual value of -$6.5 million for FY2024, which is 21992.57% down from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Change in Cash is $13.0 million, which was up 30493.69% from $5.9 million recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Change in Cash high stood at $80.3 million for Q1 2024, and its period low was -$72.3 million during Q2 2024.
  • Over the past 5 years, Celldex Therapeutics' median Change in Cash value was -$6.3 million (recorded in 2024), while the average stood at -$410473.7.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 93330.12% in 2023, then surged by 30493.69% in 2025.
  • Over the past 5 years, Celldex Therapeutics' Change in Cash (Quarter) stood at -$33.0 million in 2021, then skyrocketed by 132.83% to $10.8 million in 2022, then rose by 26.13% to $13.7 million in 2023, then plummeted by 158.79% to -$8.0 million in 2024, then surged by 261.54% to $13.0 million in 2025.
  • Its last three reported values are $13.0 million in Q3 2025, $5.9 million for Q2 2025, and -$11.2 million during Q1 2025.